Effectiveness of Chinese herbal medicine for cancer palliative care: overview of systematic reviews with meta-analyses

Vincent CH Chung1,2, Xinyin Wu1,2, Edwin P. Hui1,3, Eric TC Ziea4, Bacon FL Ng4, Robin ST Ho2, Kelvin KT Tsoi2,5, Samuel YS Wong1,2 & Justin CY Wu1,6

Chinese herbal medicines (CHM) are often used in managing cancer related symptoms but their effectiveness and safety is controversial. We conducted this overview of meta-analyses to summarize evidence on CHM for cancer palliative care. We included systematic reviews (SRs) with meta-analyses of CHM clinical trials on patients diagnosed with any type of cancer. Methodological quality of included meta-analyses was assessed with the Methodological Quality of Systematic Reviews (AMSTAR) Instrument. Fifty-one SRs with meta-analyses were included. They covered patients with lung (20 SRs), gastric (8 SRs), colorectal (6 SRs), liver (6 SRs), breast (2 SRs), cervical (1 SR), esophageal (1 SR), and nasopharyngeal (1 SR) cancers. Six SRs summarized evidence on various types of cancer. Methodological quality of included meta-analyses was not satisfactory. Overall, favorable therapeutic effects in improving quality of life among cancer patients have been reported. Conflicting evidence exists for the effectiveness of CHM in prolonging survival and in reducing chemotherapy and/or radiotherapy related toxicities. No serious adverse effects were reported in all included studies. Evidence indicated that CHM could be considered as an option for improving quality of life among patients receiving palliative care. It is unclear if CHM may increase survival, or reduce therapy related toxicities.

Defined as “total care” by the World Health Organization1, the primary aims of palliative care are to promote adequate symptom control and to optimize quality of life before a “timely, dignified and peaceful death” in people with cancer2. Early, appropriate palliative cancer care can reach the goal of improving quality of life, increasing survival time, and reducing the need of aggressive care during the end of life3. Current model has shifted from confining palliative cancer care to the last 6 months of life to the whole disease trajectory4. Growing number of aging populations with increasing prevalence of cancer have made palliative care a global health priority5,6. While the role of palliative care is widely recognized, effective palliative care interventions are sparse7,8.

In view of limitations in conventional palliative care, the potential role of traditional Chinese medicine can be explored. It has long been used as a supportive intervention for cancer patients in China and other Asian countries9. It is also becoming popular in western countries in palliative cancer care10. As one of the major treatment modalities in traditional Chinese medicine, Chinese herbal medicine (CHM) has been widely used as adjuvant cancer treatment among Chinese communities9,11. Numerous systematic reviews (SRs) have been conducted to synthesize the effectiveness of CHM in palliative cancer care. One of the SRs published in English has synthesized evidence on the effectiveness of CHM on cancer symptom management. The results indicated mixed results for improving nutritional status, pain and quality of life but it is likely to be outdated12. There are also some reports on CHM's effectiveness in reducing side effect of chemotherapy and in improving survival13.

1 Hong Kong Institute of Integrative Medicine, The Chinese University of Hong Kong, Hong Kong. 2 Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong. 3 Comprehensive Cancer Trials Unit, The Chinese University of Hong Kong, Hong Kong. 4 Chinese Medicine Department, Hong Kong Hospital Authority, Hong Kong. 5 Big Data Decision Analytics Research Centre, The Chinese University of Hong Kong, Hong Kong. 6 Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong. Correspondence and requests for materials should be addressed to X.W. (email: wuxinyin@cuhk.edu.hk)
We conducted an overview of meta-analysis to critically appraise and summarize clinical evidence on CHM for cancer palliative care. We aim to provide a broad overview on available evidence, which will inform clinicians, cancer patients and policy makers, and to identify methodological limitations of existing SRs so as to guide future research in this area.

**Results**

**Characteristics of included SRs.** A total of 844 citations were retrieved from the databases, among which 51 SRs met the inclusion criteria and were included in this overview (Fig. 1). The 51 included SRs were published between 2004 and 2014, with 34 (66.7%) published after 2012. Characteristics of these SRs can be found in Table 1. Eleven SRs (21.6%) were published in English and the remaining 40 (80.4%) were published in Chinese. Thirty-six SRs (70.6%) searched both international and Chinese databases and 30 of them (83.3%) reported the publication languages of included studies, with 24 (80.0%) only identified Chinese publications. Two (3.9%) were Cochrane SRs. Thirty-seven (72.5%) SRs only included randomized controlled trials (RCTs) while the remaining 14 (27.5%) included both RCTs and non-RCTs. Among 48 SRs that provided a cutoff date on literature search, 29 (60.4%) conducted literature search after 2011 with the most recent search conducted in January 2013. Lists of the included SRs were shown in Appendix 3.

Twenty (39.2%) SRs only included lung cancer patients, among which 19 SRs specifically focused on non-small cell lung cancer (NSCLC) patients. The remaining 31 SRs summarized evidence on patients with gastric (8 SRs), colorectal (6 SRs), liver (6 SRs), breast (2 SRs), cervical (1 SR), esophageal (1 SR), and nasopharyngeal (1 SR) cancers. Six SRs summarized evidence on various types of cancer.

All CHM interventions were used as an adjuvant therapy in the included SRs, with comparisons being CHM plus chemotherapy and/or radiotherapy versus chemotherapy and/or radiotherapy alone. Details on CHM evaluated can be found in Table 1. Twenty-eight SRs reviewed a single, specific type of CHM treatment, while the remaining 23 SRs summarized evidence on various types of CHM. Details of CHM reviewed in the 23 SRs were shown in Appendix 4.

Three types of outcomes were summarized among identified SRs, with 29 SRs provided results on quality of life (QoL), 23 SRs on survival rate and 11 SRs on chemotherapy and/or radiotherapy induced toxicity. These toxicities

---

**Figure 1.** Flowchart of literature selection on meta-analyses of Chinese herbal medicines for cancer palliative care. Keys: CHM, Chinese herbal medicine; SR, systematic review.
| First author and year of publication | Included study design | Search period | Cancer site (tumor stage) | No. of studies (No. of patients) | Nature of Chinese herbal medicine (CHM) interventions<sup>a</sup> | Nature of control interventions | Outcomes reported |
|------------------------------------|----------------------|---------------|--------------------------|-------------------------------|----------------------------------------------------------|-----------------------------|------------------|
| Ma, 2004                           | RCT or quasi-RCT     | 2003          | NSCLC (TNM III–IV)       | 10 (771)                      | CHM + chemotherapy (Cisplatin drugs)                      | Cisplatin drugs chemotherapy alone | QOL              |
| Liu, 2009                          | RCT                  | Sep. 2007     | CRC (NR)                 | 6 (334)                       | Jianpi CHM + chemotherapy                                | Chemotherapy alone           | QOL              |
| Wu, 2009a                          | RCT                  | Jul. 2008     | NSCLC (TNM III–IV)       | 19 (1380)                     | Aidi injection + NP chemotherapy                         | NP chemotherapy alone        | QOL              |
| Wu, 2009b                          | RCT                  | Feb. 2009     | Liver cancer (TNM III–IV)| 45 (3236)                     | CHM + TACE                                               | TACE alone                   | Survival rate    |
| Zhu, 2009                          | RCT or quasi-RCT     | Aug. 2008     | NSCLC (TNM III–IV)       | 16 (1041)                     | KLT + NP or MVP or GP chemotherapy                      | NP or MVP or GP chemotherapy alone | QOL              |
| Chen, 2010                         | RCT                  | Oct. 2009     | NSCLC (NR)               | 11 (796)                      | CHM + MYP or NP chemotherapy                            | MYP or NP chemotherapy alone | Survival rate    |
| Dong, 2010a                        | RCT or quasi-RCT     | NR            | Various (NR)             | 12 (1230)                     | Astragalus injection + chemotherapy                     | Chemotherapy alone           | QOL, chemotherapy related toxicity: leucopenia, anemia, thrombocytopenia, and nausea and vomiting |
| Fu, 2010                           | RCT                  | Oct. 2009     | Various (NR)             | 24 (4150)                     | CHM + chemotherapy                                      | Chemotherapy alone or Chemotherapy + placebo | Chemotherapy related toxicity: leucopenia, thrombocytopenia |
| Guo, 2010                          | RCT                  | 2009          | Liver cancer (NR)        | 33 (2619)                     | CHM + TACE                                              | TACE alone or TACE + placebo | QOL              |
| Zhou, 2010                         | RCT                  | NR            | Gastric cancer (NR)      | 13 (877)                      | CHM + chemotherapy                                      | Chemotherapy alone           | Survival rate    |
| Dong, 2010b                        | RCT                  | Apr. 2010     | NSCLC (TNM III–IV)       | 29 (2062)                     | SFI + platinum containing chemotherapy                 | Platinum containing chemotherapy alone | QOL, chemotherapy related toxicity: leucopenia, anemia, thrombocytopenia, and nausea and vomiting |
| Cui, 2011                          | RCT                  | Dec. 2010     | NSCLC (TNM III–IV)       | 9 (584)                       | KS + NP chemotherapy                                     | NP chemotherapy alone        | QOL              |
| Ma, 2011a                          | RCT                  | Jun. 2010     | NSCLC (TNM III–IV)       | 11 (752)                      | KS + NP chemotherapy                                     | NP chemotherapy alone        | QOL              |
| Ma, 2011b                          | RCT                  | Jun. 2010     | Liver cancer (NR)        | 11 (NR)                       | KS + TACE                                               | TACE alone                   | QOL, survival rate |
| Wang, 2011                         | RCT                  | Aug. 2010     | Gastric cancer (NR)      | 4 (304)                       | KLT + chemotherapy                                      | Chemotherapy alone           | Survival rate    |
| Qiao, 2011                         | RCT or quasi-RCT     | Mar. 2010     | Nasopharyngeal cancer (TNM I–IV) | 9 (795)                      | Yiqi Yangyn and Qingre Huox/e decoction + radiotherapy | Radiotherapy alone           | QOL, survival rate |
| Zhuang, 2011                       | RCT or quasi-RCT     | Nov. 2010     | NSCLC (TNM III–IV)       | 6 (416)                       | Kang Ai injection + TP                                  | TP chemotherapy alone        | QOL              |
| Guo, 2012                          | RCT or quasi-RCT     | Aug. 2011     | CRC (TNM IV)             | 20 (1304)                     | CHM + chemotherapy or radiotherapy                      | Chemotherapy or radiotherapy | Survival rate, QOL |
| Jin, 2012                          | RCT                  | Oct. 2011     | Various (NR)             | 5 (373)                       | Extract of *Ganoderma lucidum* (chemotherapy or radiotherapy) | Chemotherapy + placebo or chemotherapy alone or radiotherapy + conventional care | QOL              |
| Yang, 2012                         | RCT or quasi-RCT     | 2006          | Lung cancer (NR)         | 10 (853)                      | CHM* + chemotherapy or radiotherapy or both             | Chemotherapy or radiotherapy or both | Survival rate    |
| Qin, 2012                          | RCT                  | Oct. 2011     | NSCLC (TNM III–IV)       | 13 (972)                      | Kang Ai injection + paclitaxel or gemcitabine or navelbin + platinum containing chemotherapy | Paclitaxel or gemcitabine or navelbin + platinum containing chemotherapy alone | QOL              |
| Cai, 2012                          | RCT                  | 2011          | Gastric cancer (TNM I–IV)| 9 (NR)                        | SFI + chemotherapy                                      | Chemotherapy alone           | QOL              |
| Wang, 2012a                        | RCT or quasi-RCT     | 2010          | CRC (NR)                 | 9 (518)                       | CHM + chemotherapy                                      | Chemotherapy alone           | QOL              |
| Li, 2012a                          | RCT or quasi-RCT     | 2011          | CRC (NR)                 | 14 (1081)                     | CHM + chemotherapy                                      | Chemotherapy alone           | Survival rate    |
| Li, 2012b                          | RCT                  | Aug. 2011     | Liver cancer (NR)        | 47 (3854)                     | CHM + TACE                                              | TACE alone                   | Survival rate, chemotherapy related toxicity: leucopenia, anemia, thrombocytopenia |
| Lin, 2012                          | RCT                  | 2011          | Breast cancer (NR)       | 6 (NR)                        | KS + chemotherapy                                      | Chemotherapy alone           | QOL              |
| Fan, 2012                          | RCT                  | Jun. 2011     | Breast cancer (TNM I–IV)| 6 (496)                       | KS + chemotherapy                                      | Chemotherapy alone           | QOL              |
| Ma, 2012                           | RCT                  | Jun. 2010     | NSCLC (TNM III–IV)       | 8 (696)                       | KS + TP chemotherapy                                    | TP chemotherapy alone        | QOL              |
| Shi, 2012                          | RCT or quasi-RCT     | 2010          | Gastric cancer (NR)      | 21 (1178)                     | CHM + chemotherapy                                      | Chemotherapy alone           | Survival rate, Chemotherapy related toxicity: leucopenia, anemia, thrombocytopenia. |

Continued
| First author and year of publication | Included study design | Search period | Cancer site (tumor stage) | No. of studies (No. of patients) | Nature of Chinese herbal medicine (CHM) interventionsa | Nature of control interventions | Outcomes reported |
|-------------------------------------|----------------------|---------------|--------------------------|---------------------------------|---------------------------------|-------------------------------|-------------------|
| Wang, 2012b                        | RCT                  | Jun. 2012     | Gastric cancer (TNM III–IV) | 44 (3088)                       | CHM + conventional care         | Conventional care alone      | QOL               |
| Rong, 2012                          | RCT                  | Nov. 2011     | NSCLC (TNM III–IV)         | 18 (1108)                       | CHM + Chemotherapy              | Chemotherapy alone           | Survival rate     |
| Wang, 2012c                         | RCT or quasi-RCT     | Sep. 2011     | Various (NR)               | 11 (618)                        | Xiaoaiping injection + chemotherapy | Chemotherapy alone           | QOL               |
| Zhang, 2012                         | RCT                  | Dec. 2011     | Various (TNM II–IV)        | 16 (1539)                       | SFI + chemotherapy or radiotherapy | Chemotherapy or radiotherapy alone | QOL               |
| Xu, 2012                            | RCT or quasi-RCT     | NR            | Cervical cancer (TNM II–IV) | 18 (1657)                       | CHM + radiotherapy or CHM + radiotherapy + conventional care | Radiotherapy alone or radiotherapy + conventional care | Survival rate     |
| Cheung, 2013                        | RCT                  | Oct. 2012     | Liver cancer (TNM II–IV)   | 67 (5211)                       | CHM + TACE                       | TACE alone                   | QOL, survival rate, Chemotherapy related toxicity: nausea and vomiting |
| Li, 2013                            | RCT                  | Sep. 2012     | NSCLC (TNM III–IV)         | 24 (NR)                         | CHM + chemotherapy              | Chemotherapy alone           | QOL, survival rate, Chemotherapy related toxicity: nausea and vomiting, leucopenia, anemia and thrombocytopenia. |
| Xie, 2013                           | RCT or quasi-RCT     | Jan. 2013     | Gastric cancer (TNM III–IV) | 15 (1008)                       | Huachansu + chemotherapy        | Chemotherapy alone           | Survival rate     |
| Du, 2013                            | RCT                  | 2012          | Esophageal cancer (NR)     | 5 (NR)                          | KS + chemotherapy or radiotherapy | chemotherapy or radiotherapy alone | Survival rate     |
| Tian, 2013                          | RCT                  | Nov. 2012     | NSCLC (NR)                 | 24 (1845)                       | CHM + chemotherapy or radiotherapy | chemotherapy alone or chemotherapy + radiotherapy | Survival rate     |
| Jiang, 2013                         | RCT                  | 2013          | Liver cancer (NR)          | 16 (1105)                       | CHM + TACE                       | TACE alone                   | Survival rate     |
| Liu, 2013                           | RCT or quasi-RCT     | 2012          | NSCLC (NR)                 | 6 (346)                         | Zilongtian (bailongtian) + chemotherapy | chemotherapy (GP, NP or MVP) alone | QOL               |
| Xu, 2013                            | RCT                  | Oct. 2012     | Gastric cancer (NR)        | 15 (NR)                         | CHM + Chemotherapy               | Chemotherapy alone           | QOL               |
| Xiao, 2013                          | RCT                  | 2012          | NSCLC (NR)                 | 10 (588)                        | Xiaoaiping injection + platinum containing chemotherapy | Platinum containing chemotherapy alone | QOL               |
| Su, 2013                            | RCT or quasi-RCT     | Oct. 2012     | Various (NR)               | 82 (NR)                         | KS + chemotherapy or radiotherapy | Chemotherapy or radiotherapy alone | Survival rate     |
| Yan, 2013                           | RCT                  | Feb. 2012     | NSCLC (TNM III–IV)         | 10 (687)                        | KLT + NP chemotherapy           | NP chemotherapy alone        | QOL               |
| Sheng, 2013                         | RCT                  | 2011          | NSCLC (NR)                 | 38 (NR)                         | SFI + chemotherapy (GP or NP or TP or DP) | Chemotherapy (GP or NP or TP or DP) alone | QOL               |
| He, 2013                            | RCT                  | Sep. 2012     | NSCLC (TNM III–IV)         | 19 (1110)                       | Shenfu injection + platinum containing chemotherapy | Platinum containing chemotherapy alone | QOL               |
| Chen, 2014                          | RCT                  | Dec. 2012     | CRC (TNM IV)               | 13 (940)                        | CHM + FOLFOX 4                   | FOLFOX4 alone                | Survival rate, Chemotherapy related toxicity: neutropenia, nausea and vomiting, neurotoxicity, diarrhea, anemia, thrombocytopenia, and stomatitis |
| Xu, 2014                            | RCT                  | Dec. 2012     | NSCLC (TNM III–IV)         | 17 (1605)                       | KLT + chemotherapy              | Chemotherapy alone           | QOL               |
| Liu, 2014                           | RCT                  | Jun. 2012     | CRC (TNM IV)               | 13 (781)                        | CHM + chemotherapy              | Chemotherapy alone           | Survival rate     |
| Wang, 2014                           | RCT                  | 2012          | Gastric cancer (TNM III–IV) | 10 (1020)                       | SFI + FOLFOX4                    | FOLFOX4 alone                | QOL               |

Table 1. Characteristics of included meta-analyses on Chinese herbal medicine for cancer palliative care.

a Included all types of CHM. CHM denotes the inclusion of all types of Chinese herbal medicines. The use of generic terms “chemotherapy” or “radiotherapy” denotes that the specific treatments used were not described in the original meta-analyses publications. Keys: CHM, Chinese herbal medicine; CRC, colorectal cancer; DP, Docetaxel + Cisplatin; FOLFOX, the FOLFOX regimen refers to 5-Fluorouracil + Leucovorin combined with Oxaliplatin; GP, Gemcitabine + Cisplatin; KLT, Kanglaite injection; KS, Compound Kushen injection; MVP, Mitomycin + Vinorelbine + Cisplatin; NP, Cisplatin + Vinorelbine; NR, not reported; NSCLC, non-small lung cell cancer; QOL, quality of life; RCT, randomized controlled trial; SFI, Shenqi Fuzheng injection; SR, systematic review; TACE, Transcatheter arterial chemoembolization; TNM, tumor-node-metastasis stage; TP, Paclitaxel + Cisplatin.
| First author and year of publication | AMSTAR item |
|-------------------------------------|-------------|
| Ma, 2004                            | N NR Y NR N N N Y N N |
| Liu, 2009                           | N Y Y N N N Y N N |
| Wu, 2009a                           | N NR NR NR N N Y Y NR Y N |
| Wu, 2009b                           | N Y Y Y N N NR Y NR Y N |
| Zhu, 2009                           | N NR Y Y N N Y Y Y Y N |
| Chen, 2010                          | N NR N NR N N N N N Y N |
| Dong, 2010                          | N Y Y Y N N Y N Y N N |
| Fu, 2010                            | N Y Y N N N Y N Y Y N |
| Guo, 2010                           | N NR Y NR N N Y Y N Y N |
| Zhou, 2010                          | N NR Y N N N Y Y N Y N |
| Dong, 2010                          | N Y Y N N Y Y Y Y N N |
| Cai, 2011                           | N Y Y Y N N Y Y Y N N |
| Ma, 2011a                           | N NR Y NR N N Y Y Y Y N |
| Ma, 2011b                           | N NR Y NR N N Y Y Y Y N |
| Wang, 2011                           | N Y Y NR N N Y Y N Y N |
| Qiao, 2011                           | N Y Y N N Y Y Y Y N N |
| Zhuang, 2011                        | N Y Y NR N N Y Y Y Y N |
| Qin, 2012a                          | Y Y Y Y Y Y Y N Y N |
| Jin, 2012                           | Y Y Y Y Y Y N Y N |
| Yang, 2012                          | N NR Y N N N Y N Y N |
| Qin, 2012b                          | N NR Y N N N Y Y Y N |
| Cai, 2012                           | N Y Y Y N N Y Y Y N N |
| Wang, 2012a                         | N NR Y N N N Y Y Y Y N |
| Li, 2012a                           | N Y Y N N N Y Y Y Y N |
| Li, 2012b                           | N Y Y Y N N Y Y Y Y N |
| Liu, 2012                           | N NR Y N N N Y Y Y Y N |
| Fan, 2012                           | N NR Y Y N N Y Y Y N |
| Ma, 2012                            | N NR Y NR N N Y Y Y N |
| Shi, 2012                           | N Y Y N N N Y N Y N |
| Wang, 2012b                         | N Y Y N N N NR N Y Y N |
| Rong, 2012                          | N Y Y N N N Y Y Y N |
| Wang, 2012c                         | N NR Y N N N Y N Y Y |
| Zhang, 2012                         | N Y Y N N Y Y Y Y Y |
| Xu, 2012                            | N Y Y Y Y N N Y Y Y N |
| Cheung, 2013                        | N Y Y Y N N Y Y Y N |
| Li, 2013                            | N Y Y NR N Y Y Y Y N |
| Xie, 2013                           | N Y Y Y N N NR N NR Y |
| Du, 2013                            | N Y Y NR N N Y Y N Y |
| Tian, 2013                          | N Y Y Y N N Y Y Y Y N |
| Jiang, 2013                         | N NR Y N N N Y Y Y N |
| Liu, 2013                           | N Y Y Y N N Y Y N N |
| Xu, 2013                            | N NR Y N N N Y N N |
| Xiao, 2013                          | N Y Y Y Y N N Y Y Y N |
| Su, 2013                            | N Y Y NR N Y Y Y Y Y N |
| Yan, 2013                           | N NR Y NR N N Y Y Y N |
| Sheng, 2013                         | N Y Y Y N N Y Y Y N |
| He, 2013                            | N Y Y Y N Y Y Y Y Y N |
| Chen, 2014                          | N Y Y N Y Y Y Y NR Y |
| Xu, 2014                            | N Y Y N N Y Y N N N |
| Liu, 2014                           | N NR Y NR N N NR N Y N N |
| Wang, 2014                           | N Y Y N N Y Y Y Y Y N |
| # of Yes (%)                        | 2 (3.9) 32 (62.7) 49 (96.1) 19 (37.3) 2 (3.9) 16 (31.4) 44 (86.3) 31 (60.8) 39 (76.5) 33 (64.7) 0 (0.0) |

Table 2. Methodological quality of included meta-analyses on Chinese herbal medicine for cancer palliative care. Keys: CHM, Chinese herbal medicine; N, no; NR, not reported; Y, yes (meta-analysis fulfilling the criteria); # of Yes, number of yes; AMSTAR item: 1. Was an ‘a priori’ design provided? 2. Was there duplicate study selection and data extraction? 3. Was a comprehensive literature search performed? 4. Was
the status of publication (i.e. grey literature) used as an inclusion criterion? 5. Was a list of studies (included and excluded) provided? 6. Were the characteristics of the included studies provided? 7. Was the scientific quality of the included studies assessed and documented? 8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 9. Were the methods used to combine the findings of studies appropriate? 10. Was the likelihood of publication bias assessed? 11. Was the conflict of interest included?

| Effectiveness of CHM for cancer palliative care. | Methodological quality of included SRs. |
|------------------------------------------------|----------------------------------------|
| All included SRs used similar criteria for measuring the outcomes. QoL was assessed with the Karnofsky Performance Status (KPS) scale. A KPS score increment >10 score was defined as clinical improvement, while patients with KPS score increment >0 were considered as respondents. Survival was measured with survival rate across the follow up duration. Chemotherapy toxicities were measured by the World Health Organization toxicity criteria. Details on the effectiveness as well as quality of evidence of CHM for improving QoL and survival rate; and in reducing chemotherapy and/or radiotherapy related toxicities are shown in Tables 3–5. In the paragraphs below, abbreviation of the CHM is used if the SR focused specifically on one particular type of CHM. The general term of “CHM” is used if the SR provided evidence on various type of CHM. |
| Methodological quality of included SRs was shown in Table 2. Forty-nine (96.1%) SRs performed a comprehensive literature search. Forty-four (86.3%) SRs assessed and documented risk of bias among included studies. Thirty-nine (76.5%) SRs used appropriate methods to combine the findings. Nineteen (37.3%) SRs did not search for grey literature. Sixteen (31.4%) SRs provided the characteristics of included studies. Only two SRs (3.9%) provided a protocol. Although 39 (76.5%) SRs listed all included studies, only two (3.9%) provided a list of both included and excluded studies. No SRs stated conflict of interest for both the SR and the included studies. Nine (17.6%) stated conflict of interest for the SR itself, eight of which were published in English and only one was published in Chinese. |

**QoL. NSCLC.** Fourteen SRs summarized evidence on CHM as an adjuvant intervention for improving QoL in NSCLC patients. These 14 SRs reviewed the effects of Compounds Kushen injection (KS) (3 SRs), Kanglaite injection (2 SRs), Shenqi Fuzheng injection (SFI) (2 SRs), Kang Ai injection (2 SRs), Zijinglong (1 SR), Xiaoaiping (1 SR), Shenfu injection (1 SR). Two reviewed mixed types of CHM. When compared to chemotherapy alone, combination of CHM and chemotherapy significantly improved QoL as shown in the meta-analyses results. All but two meta-analyses showed homogeneity, with $I^2$ values of 57.0% and 77.0% respectively.

**Liver cancer.** Three SRs summarized the add-on effects of CHM on QoL in liver cancer patients. One SR focused on KS and the other two reviewed a range of CHM. Meta-analyses from these three SRs showed that patients treated with KS or CHM plus transcatheter chemoembolization (TACE) had significantly greater improvement on QoL than those who received TACE alone. One SR also showed that CHM plus TACE provided a significantly higher increment on KPS score (pooled MD = 10.03, 95% CI = 8.98–11.07) than TACE alone. Nevertheless, high level of heterogeneity ($I^2 = 95\%, p < 0.001$) exist in this meta-analysis.

**Gastric cancer.** Two SRs reviewed the evidence of SFI plus chemotherapy for improving QoL among gastric cancer patients. Meta-analyses showed promising effect of SFI in both SRs. One which included TNM stage I–IV patients showed a significantly improved response (improvement rate, pooled RR = 3.14, 95% CI = 2.11–4.69). The other one which only included TNM stage III–IV patients demonstrated a significant, yet lesser effect (responder rate, pooled OR = 1.48, 95% CI = 1.26–1.57). Another SR which included various type of CHM found that, when compared to conventional care alone, combination of CHM and conventional care can slightly improve QoL score (pooled MD = 0.51, 95% CI = 0.21–1.82) in TNM stage III–IV patients. High heterogeneity ($I^2 = 86\%, p < 0.01$) was observed for this meta-analyses.

**Colorectal cancer.** Two SRs have reported add-on benefit of CHM in improving QoL. One Cochrane SR summarized evidence on advanced colorectal cancer patients, who are diagnosed as reaching stage IV in the American Joint Committee on Cancer Staging System or stage D with Union Internationale Contrele Cancer. The other SR did not provide tumor stage of included patients.

**Breast cancer.** Two SRs reported that, when compared to chemotherapy alone, KS plus chemotherapy significantly improved QoL in breast cancer patients.

**Nasopharyngeal cancer.** One SR summarized evidence of various CHM for improving QoL in patients with nasopharyngeal cancer. Meta-analysis showed that, the combination of CHM and radiotherapy led to a slight improvement in patients’ QoL (pooled RR = 1.60, 95% CI = 1.30–1.96) when compared to radiotherapy alone.

**Various types of cancer.** Four SRs reviewed the add-on effect of CHM on QoL among patients with different diagnoses. All SRs reported the add-on benefit of CHM on top of chemotherapy or radiotherapy in improving QoL, when compared to chemotherapy or radiotherapy alone. These SRs studied astragalus injection, Reishi mushroom extract, Xiaoaiping injection and SFI respectively.
### Table 3. Chinese Herbal Medicine for Improving QOL among Cancer Patients: Overview of Meta-Analyses Results

QOL measured with the Karnofsky Performance Status (KPS) scale. A KPS score increment >10 is defined as an improvement. Improvement rate = number of patients who had a KPS increment >10 / total number of patients, this definition apply to all improvement rate in Table 3. *A KPS score increment >0 is defined as an improvement. Responder rate = number of patients who had a KPS increment >0 / total number of patients, this definition apply to all improvement rate in Table 3. **CHM denotes the inclusion of all types of Chinese herbal medicines. The use of generic terms “chemotherapy” in this context refers to 5-Fluorouracil (5-FU) combined with Leucovorin combined with Oxaliplatin; KLT, Kanglaite injection; KS, Compound Mitomycin + Vinorelbine; MVP, Mitomycin + Vincristine + Vindesine + Cisplatin; NR, not reported; OR, odds ratio; QOL, quality of life; RR, relative risk; SFI, Shenqi Fuzheng injection; TACE, Transcatheter arterial chemoembolization; TP, Paclitaxel + Cisplatin.*
| First author and year of publication | Comparison | Duration of follow up (year) | No. of studies (No. of patients) | Pooled results (95% CI) | Heterogeneity I2 (%) | Quality of evidence |
|-------------------------------------|------------|----------------------------|--------------------------------|-------------------------|---------------------|-------------------|
| **Non-small cell lung cancer**      |            |                            |                                |                         |                     |                   |
| Chen, 2010                          | CHM + chemotherapy vs. chemotherapy | 1                           | 4(338)                         | OR: 1.29 [0.83, 2.01]  | 0.0                 | Low               |
| Rong, 2012                          | CHM + chemotherapy vs. chemotherapy | 2                           | 2(180)                         | OR: 2.26 [1.16, 3.99]  | 58.                 | Low               |
| Li, 2013                            | CHM + chemotherapy vs. chemotherapy | 1                           | 5(NR)                          | RR: 1.35 [1.09, 1.66]  | 0.0                 | Moderate          |
| Tian, 2013                          | CHM + chemotherapy vs. chemotherapy | 1                           | 7(608)                         | RR: 1.36 [1.15, 1.60]  | 0.0                 | Moderate          |
| **Liver cancer**                    |            |                            |                                |                         |                     |                   |
| Yang, 2012                          | CHM + chemotherapy vs. chemotherapy | 2                           | 4(406)                         | OR: 3.44 [2.04, 5.80]  | 0.0                 | Moderate          |
| Wu, 2009b                           | CHM + TACE vs. TACE                  | 0.5                          | 15(NR)                         | RR: 1.10 [1.04, 1.15]  | 0.0                 | Moderate          |
| Ma, 2011b                           | KS + TACE vs. TACE                   | 1                            | 4(283)                         | OR: 2.18 [1.29, 3.69]  | 0.0                 | High              |
| Li, 2012b                           | CHM + TACE vs. TACE alone or TACE + conventional care | 1 | 17(1238) | RR: 1.36 [1.25, 1.49]  | 15.0                | Moderate          |
| **Gastric cancer**                  |            |                            |                                |                         |                     |                   |
| Zhou, 2010                          | CHM + chemotherapy vs. chemotherapy | 3                           | 4(409)                         | OR: 2.33 [1.53, 3.56]  | 22.4                | Moderate          |
| Wang, 2011                          | KLT + chemotherapy vs. chemotherapy | 1                           | 2(94)                          | OR: 6.74 [2.74, 16.62] | 0.0                 | High              |
| Shi, 2012                           | CHM + chemotherapy vs. chemotherapy | 1                           | 3(289)                         | OR: 1.10 [1.01, 1.21]  | 0.0                 | Low               |
| Xie, 2013                           | Huachansu + chemotherapy vs. chemotherapy | 1 | 4(NR)  | RR: 1.25 [0.73, 2.14]  | 0.0                 | Moderate          |
| Xu, 2013                            | CHM + chemotherapy vs. chemotherapy | 1                           | 4(399)                         | OR: 2.17 [1.15, 4.08]  | 0.0                 | Moderate          |
| **Colorectal cancer**               |            |                            |                                |                         |                     |                   |
| Guo, 2012                           | CHM + chemotherapy vs. chemotherapy | 1                           | 4 (238)                        | RR: 1.39 [1.15, 1.69]  | NR                  | Moderate          |
| Li, 2012a                           | CHM + chemotherapy vs. chemotherapy | 0.5                          | 3(134)                         | OR: 2.19 [1.10, 4.34]  | 0.0                 | High              |

| Continued                           |            |                            |                                |                         |                     |                   |
| First author and year of publication | Comparison* | Duration of follow up (year) | No. of studies (No. of patients) | Pooled results (95% CI) | Heterogeneity I² (%) | Quality of evidence |
|-------------------------------------|-------------|-------------------------------|---------------------------------|-------------------------|----------------------|--------------------|
| Qiao, 2011                          | CHM + chemotherapy vs. chemotherapy | 3                             | 8(657)                          | OR: 2.25[1.54, 3.30]   | 0.0                  | High               |
| CHM + chemotherapy vs. chemotherapy | 4           | 1(122)                        | OR: 2.29[1.08, 4.82]            | NA                     | High                 |
| CHM + chemotherapy vs. chemotherapy | 5           | 4(394)                        | OR: 2.32[1.55, 3.48]            | 0.0                    | High                 |
| Chen, 2014                          | CHM + FOLFOX4 vs. FOLFOX4          | 1                             | 3(279)                          | RR: 1.51[1.19, 1.90]   | 0.0                  | Moderate           |
| Liu, 2014                           | CHM + chemotherapy vs. chemotherapy | 1                             | 4(339)                          | OR: 2.60[1.46, 4.63]   | 29.0                 | Moderate           |

**Table 4. Chinese Herbal Medicine for Improving Survival Rate among Cancer Patients: Overview of Meta-Analyses Results.** *p < 0.05 for the heterogeneity test; CHM denotes the inclusion of all types of Chinese herbal medicines. The use of generic terms “chemotherapy” or “radiotherapy” denote that the specific treatments used were not described in the original meta-analyses publications. Effects on dichotomous data were summarized with risk ratio (RR) or odds ratio (OR) to measure the risk of experiencing certain outcome in the treatment group as compared to the control group. Keys: CHM, Chinese herbal medicine; CI confidence interval; FOLFOX, the FOLFOX regimen refers to 5-Fluorouracil + Leucovorin combined with Oxaliplatin; KLT, Kanglaite injection; KS, Compound Kushen injection; NR, not reported; OR, odds ratio; RR, relative risk; TACE, Transcatheter arterial chemoembolization.

**Quality of evidence.** Majority (93.5%) of the evidence reviewed is of moderate quality. Evidence on gastric cancer is of low quality, and in another SR on various types of cancer the evidence is of high quality.

**Survival rate.** NSCLC. Four SRs reviewed various types of CHM plus chemotherapy versus chemotherapy alone for improving survival rate among NSCLC patients. All SRs showed that additional CHM treatment can slightly improve 1-year survival rate, although one SR reported that the benefit were not of significance. Other pooled results also showed that, CHM plus chemotherapy can significantly improve 2-year (pooled OR = 2.26, 95% CI = 1.16–3.99), 3-year (pooled OR = 2.59, 95% CI = 1.51–4.45) and 5-year (pooled OR = 2.45, 95% CI = 1.24–4.84) survival rates when compared to chemotherapy alone.

Lung cancer. One SR summarized evidence of various types of CHM plus chemotherapy or and radiotherapy versus chemotherapy or radiotherapy alone for improving survival rate in lung cancer patients. Meta-analysis showed that CHM provide an add-on benefit in improving 2-year survival rate (pooled OR = 3.44, 95% CI = 2.04–5.80).

Liver cancer. Five SRs reviewed evidence of CHM plus TACE versus TACE alone for improving survival rate. CHM interventions included KS and mixed types of CHM. Meta-analyses showed that CHM provided additional benefits in improving 0.5-year, 1-year, 1.5-year, 2-year and 3-year survival rates. It should be noted that significant heterogeneities were found in three meta-analyses: 1.5-year survival rate ($I^2 = 70\%$, $p = 0.009$) in Wu 2009 b, 1.5-year survival rate ($I^2 = 63\%$, $p = 0.03$) and 3-year survival rate ($I^2 = 67\%$, $p < 0.001$) in Cheung 2013.

Gastric cancer. One SR reported that Kanglaite injection plus chemotherapy provide significant improvement on 1-year survival rate of gastric cancer patients (pooled OR = 6.74, 95% CI% = 2.74–16.62) when compared to chemotherapy alone. Another SR found no significant benefit on 1-year survival rate (pooled RR = 1.25, 95% CI = 0.73–2.14) among TNM stage III–IV gastric patients using Huangchansu. Three other SRs included various types of CHM and meta-analyses showed that CHM plus chemotherapy can significantly improve 1-year, 2-year, 3-year and 5-year survival rates in gastric cancer patients.
| First author and year of publication | Cancer cite | Comparison | Outcome assessment method | No. of studies (No. of patients) | Pooled results (95%CI) | Heterogeneity (I² (%)) | Quality of evidence |
|--------------------------------------|------------|------------|---------------------------|---------------------------------|------------------------|------------------------|---------------------|
| Wu, 2009a                            | NSCLC      | Aidi injection + NP vs. NP | Grade II–IV | 10 (781) | RR: 0.52 [0.43, 0.62] | NR | Low |
| Dong, 2010b                          | NSCLC      | SFI+ platinum containing chemotherapy vs. platinum containing chemotherapy | Grade III–IV | 14 (1031) | RR: 0.32 [0.22, 0.47] | 0.0 | Moderate |
| Li, 2013                             | NSCLC      | CHM+ chemotherapy vs. chemotherapy | Grade III–IV | 6 (557) | RR: 0.34 [0.17, 0.68] | 0.0 | Moderate |
| Xu, 2014                             | NSCLC      | KLT+ chemotherapy vs. chemotherapy | Grade III–IV | 6 (494) | RR: 0.43 [0.31, 0.60] | 0.0 | Moderate |
| Li, 2012b                            | Liver cancer | CHM+ TACE vs. TACE alone or TACE+ conventional care | Grade I–IV | 11 (816) | RR: 0.79 [0.69, 0.91] | 48.0 | Moderate |
| Cheung, 2013                         | Liver cancer | CHM+ TACE vs. TACE | Grade I–IV | 9 (581) | RR: 0.86 [0.76, 0.96] | 40.0 | Moderate |
| Liu, 2009                            | CRC        | CHM+ chemotherapy vs. chemotherapy | Grade I | 6 (334) | RR: 0.85 [0.60, 1.20] | 0.0 | Moderate |
| Fu, 2010                             | Various    | CHM+ chemotherapy vs. chemotherapy | Grade I–IV | 5 (279) | OR: 0.48 [0.34, 0.66] | 0.0 | Moderate |
| Dong, 2010b                          | NSCLC      | SFI+ platinum containing chemotherapy vs. platinum containing chemotherapy | Grade III–IV | 18 (1335) | RR: 0.33 [0.21, 0.52] | 0.0 | Moderate |
| Chen, 2014                           | CRC        | CHM+ FOLFOX4 vs. FOLFOX4 | Neutropenia grade III–IV | 10 (692) | RR: 0.33 [0.18, 0.60] | 0.0 | Low |
| Shi, 2012                            | Gastric cancer | CHM+ chemotherapy vs. chemotherapy | Grade II–IV | 7 (353) | OR: 0.26 [0.18, 0.37] | 35.0 | Moderate |
| Dong, 2010a                          | Various    | Astragalus injection + chemotherapy vs. chemotherapy | Grade I–IV | 9 (927) | RR: 0.84 [0.79, 0.88] | 73.7 | Moderate |
| Fu, 2010                             | Various    | CHM+ chemotherapy vs. chemotherapy | Grade I–IV | 11 (2169) | OR: 0.40 [0.23, 0.68] | 55.0 | Moderate |

**Neutropenia**

| Li, 2009                             | CRC        | CHM+ chemotherapy vs. chemotherapy | Grade I | 5 (273) | RR: 0.84 [0.57, 1.24] | 0.0 | Low |
| Fu, 2010                             | Various    | Astragalus+ chemotherapy vs. chemotherapy | Grade I–IV | 4 (371) | RR: 0.42 [0.27, 0.65] | 33.1 | Moderate |

**Anemia**

| Dong, 2010b                          | NSCLC      | SFI+ platinum containing chemotherapy vs. platinum containing chemotherapy | Grade III–IV | 15 (1161) | RR: 0.44 [0.30, 0.66] | 0.0 | Moderate |
| Chen, 2014                           | CRC        | CHM+ FOLFOX4 vs. FOLFOX4 | Grade III–IV | 3 (220) | RR: 0.30 [0.05, 1.89] | 0.0 | Low |
| Shi, 2012                            | Gastric cancer | CHM+ chemotherapy vs. chemotherapy | Grade II–IV | 4 (207) | OR: 0.38 [0.25, 0.58] | 43.0 | Moderate |

**Neurotoxicity**

| Liu, 2009                            | CRC        | CHM+ chemotherapy vs. chemotherapy | Grade I | 5 (273) | RR: 0.84 [0.57, 1.24] | 0.0 | Low |
| Fu, 2010                             | Various    | Astragalus+ chemotherapy vs. chemotherapy | Grade I–IV | 4 (371) | RR: 0.42 [0.27, 0.65] | 33.1 | Moderate |

**Other chemotherapy related toxicity**

| Chen, 2014                           | CRC        | CHM+ FOLFOX4 vs. FOLFOX4 | Diarrhea grade III–IV | 5 (448) | RR: 0.39 [0.11, 1.42] | 0.0 | Low |
| Chen, 2014                           | CRC        | CHM+ FOLFOX4 vs. FOLFOX4 | Stomatitis grade III–IV | 2 (210) | RR: 0.43 [0.08, 2.31] | 0.0 | Low |
Colorectal cancer. Four SRs summarized evidence on the add-on effect of CHM for improving survival rate. Meta-analyses showed that CHM plus chemotherapy provide significant greater improvement on the 0.5-year, 1-year, 2-year, 3-year, 4-year and 5-year survival rates, as compared to chemotherapy alone.

Nasopharyngeal cancer. Meta-analysis from a SR showed that, when compared to radiotherapy alone, combination of CHM and radiotherapy can slightly improve 3-year survival rate (pooled RR = 1.30, 95% CI = 1.03–1.63).

Esophageal cancer. One SR summarized evidence on KS. Although the addition of KS slightly improved 3-year survival rate (pooled OR = 1.86, 95% CI = 0.96–3.62) when used on top of chemotherapy, no significant difference was found when compared to chemotherapy alone.

Cervical cancer. A SR reported that, when compared to radiotherapy or chemotherapy alone, additional CHM treatment improved patients’ 1-year survival rate significantly (pooled OR = 4.16, 95% CI = 1.97–8.78).

Various types of cancer. One SR reviewed evidence on the add-on effect of KS among patients with various types of cancer. The results showed that KS only provide a small add-on improvement for 1-year and 2-year survival rates.

Quality of evidence. Only 28.9% of the evidence on prolonging survival time showed high quality, while 60.0% is of moderate quality and the remaining 11.1% is of low quality.

Toxicities related to Chemotherapy or Radiotherapy

Leucopenia. NSCLC. Four SRs summarized evidence of the add-on effect of Aidi injection, SFI, Kanglaite injection and various types of CHM for reducing chemotherapy induced leucopenia (CIL). Meta-analyses demonstrated positive effect of these CHM in reducing CIL, but results from Kanglaite injection appeared to be heterogeneous (I² = 52%, p = 0.03). Subgroup analysis from Li 2013 showed that CHM were more effective when the baseline severity of CIL is higher (pooled RR = 0.36 in CIL grade III–IV versus pooled RR = 0.75 in CIL grade I–IV).

Colorectal cancer. Results from a SR showed that CHM tends to be more effective in treating more severe CIL, but this trend is not reflected in a subgroup analysis including only patients with grade IV CIL. Another SR showed that, when compared to FOLFOX4 (5-Fluorouracil + Leucovorin + Oxaliplatin) alone, the additional use of CHM provides significant improvement on patients with grade III–IV neutropenia.

Gastric cancer. One SR showed significant add-on benefits of CHM in reducing grade II–IV CIL (pooled OR = 0.26, 95% CI = 0.18–0.37).

Various types of cancer. A SR summarized evidence on astragalus injection plus chemotherapy versus chemotherapy alone in reducing grade I–IV CIL for various types of cancer patients. Meta-analysis showed a slight add-on benefit from astragalus injection (pooled RR = 0.84, 95% CI = 0.79–0.88). Another SR reported that, when compared to chemotherapy alone, the addition of CHM significantly improved grade I–IV CIL (pooled OR = 0.40, 95% CI = 0.23–0.68). However, both meta-analyses had significant heterogeneity.

Nausea and vomiting. NSCLC. Evidence on CHM for reducing chemotherapy induced nausea and vomiting (CINV) were reviewed on Aidi injection, SFI, Kanglaite injection and various types of CHM. All meta-analyses showed favorable effect.

Liver cancer. Two SRs reviewed evidence of CHM for treating CINV. Both showed that CHM has a slightly positive effect in reducing CINV.

Colorectal cancer. Meta-analysis from a SR showed that when compared to chemotherapy alone, combination of CHM and chemotherapy significantly reduced grade III–IV CINV. Another SR reported that CHM tended to be more effective in managing more severe CINV, although no significant difference was seen in the outcomes of patients with grade I, II or IV CINV.
**Gastric cancer.** Evidence from one SR showed that the additional use of CHM provide a protective effect against grade II–IV CINV (pooled OR = 0.48, 95% CI = 0.34–0.66).

**Thrombocytopenia.** NSCLC. Two SRs reported that SFI and various types of CHM can significantly improve thrombocytopenia in NSCLC patients.

**Colorectal cancer.** A SR included one RCT (n = 42) found that, when compared to FOLFOX4 alone, additional use of CHM has no effect in reducing grade III–IV thrombocytopenia (RR = 1.00, 95% CI = 0.07–14.95).

**Gastric cancer.** Evidence from a SR showed favorable effects of CHM in reducing grade II–IV thrombocytopenia (pooled OR = 0.35, 95% CI = 0.14–0.86).

**Various types of cancer.** Evidence showed the adjuvant use of astragalus injection or CHM can significantly reduce thrombocytopenia in cancer patients. Significant heterogeneity was seen in the first meta-analysis.

**Anemia.** NSCLC. Two SRs summarized evidence on SFI and CHM in preventing anemia. Results showed that the additional use of SFI significantly prevented the occurrence of grade III–IV anemia. However, this result is not consistent with results from another SR that summarized effects of a wide range of CHM. It is reported that CHM may significantly reduce grade I–IV anemia, but no significant difference was seen in the subgroup that only included grade III–IV patients.

**Colorectal cancer.** A SR showed that, when compared to FOLFOX4 alone, the additional use of CHM reduced the occurrence of grade III–IV anemia. However, no statistical difference was reached between the two groups.

**Gastric cancer.** Evidence from a SR showed that CHM plus chemotherapy can significantly reduce the occurrence of grade II–IV anemia, when compared to chemotherapy alone.

**Various types of cancer.** A SR suggested that the additional use of astragalus injection showed significant positive effect in reducing anemia grade I–IV in various types of cancer patients.

**Neurotoxicity.** Colorectal cancer. Although evidence showed that the additional use of CHM may reduce neurotoxicity of chemotherapy, no significant difference was reached in either of the two identified SRs.

**Other chemotherapy related toxicity.** Colorectal cancer. A SR summarized evidence on the combined use of CHM and FOLFOX4 for treating chemotherapy induced diarrhea and stomatitis in colorectal cancer patients. Although the additional use of CHM may reduce grade III–IV diarrhea and grade III–IV stomatitis, no statistical significant difference was reached in either meta-analysis.

**Quality of evidence.** More than half (65.9%) of evidence on CHM in reducing chemotherapy induced toxicity is of moderate quality, while 32.8% showed low quality and the remaining 2.3% is of very low quality.

**Adverse effect of CHM.** Among the 51 included SRs, seven (13.7%) described adverse effect from CHM usage. Three reported that no AE were described among the included RCTs. Four SRs reported a wide range of adverse effect, including nausea, insomnia, stomatitis, hair loss, mild gastric bleeding, low-grade fever, dizziness, gastrointestinal discomfort, mild skin itch and rashes. All these symptoms disappeared after discontinuing the CHM treatment, or alleviated after symptomatic treatment.

**Discussion**

This overview summarized evidence on the effect of CHM for cancer palliative care, on top of conventional treatment. We identified SRs on nine types of cancer, of which evidence on 13 specific CHM intervention were included. We also described results from SRs that did not set any restrictions on cancer diagnoses nor types of CHM interventions, which may increase the external validity of this overview as this indicates the real world practice of traditional Chinese medicine. In general, results from the identified SRs demonstrated add-on benefit of CHM in improving QoL among patients with various types of cancer, including NSCLC, liver cancer, gastric cancer, colorectal cancer, breast cancer and nasopharyngeal cancer.

For survival, it is observed that the additional use of CHM significantly improved 2-year, 3-year and 5-year survival rates in NSCLC patients, 2-year survival rate in lung cancer patients, 0.5-year, 1-year, 1.5-year, 2-year and 3-year survival rates in liver cancer patients, 2-year, 3-year, 5-year survival rates in gastric cancer patients, 0.5-year, 1-year, 2-year, 3-year, 4-year and 5-year survival rates in colorectal cancer patients, 3-year survival rate in nasopharyngeal cancer patients, 1-year survival rate in cervical cancer patients. In SRs synthesizing evidence on various types of cancer, improvement on 1-year and 2-year survival rate were also observed. However, conflicting results were observed for the 1-year survival rates of NSCLC and gastric cancer patients. Also, there seems to be no add-on effect from KS in improving 3-year survival rate of patients with esophageal cancer.

Evidence showed that the combination of CHM and chemotherapy significantly reduced leucopenia, nausea and vomiting, thrombocytopenia and anemia in NSCLC, gastric cancer patients. It also significantly reduced nausea and vomiting in liver cancer patients. In general, CHM appears to be useful in improving leucopenia, thrombocytopenia and anemia among various types of cancer. Nevertheless, available evidence cannot demonstrate clear add-on benefits of CHM in improving leucopenia, nausea and vomiting, thrombocytopenia, anemia, neurotoxicity, diarrhea and stomatitis in colorectal cancer patients.
Base on the evidence we identified, CHM may be considered as an adjuvant option to improve QoL among cancer patients. Evidence showed inconsistency in the effectiveness of CHM for improving survival rate and reducing chemotherapy and/or radiotherapy related toxicity in cancer patients. Although we attempted to include all key outcomes on cancer palliative care, only three outcomes were identified in this overview. For some common symptoms which conventional care has limited options, such as pain, fatigue, anorexia, insomnia, limbs edema and constipation, no relevant SR has been conducted. Finally, as the majority results were coming from Chinese population, the generalizability of the present results may be limited.

The methodological quality of included SRs was mediocre when compared to other SRs on CHM or those focused on conventional medicine. Good performance was noted on conducting comprehensive literature search, and on assessing and documenting risk of bias of included studies, with more than 80% SRs satisfying these two criteria. On the other hand, improvement should be made in the remaining nine AMSTAR items, especially in providing a protocol, reporting lists of both included and excluded studies, and disclosing conflict of interests for both the SR and included studies. That said, quality of evidence is not as poor as we expected. Majority of evidence on improving QoL, prolonging survival time and reducing chemotherapy induced toxicity are judged to be of moderate quality in terms of effectiveness.

In addition, reporting quality of included SRs was unsatisfactory, often with little details on CHM and conventional treatments provided, as well as on how outcomes were measured. Future SR should comply with the PRISMA statement such that it is more usable for policy makers and clinicians. Another limitation of the included SRs is that the majority of them did not mention results on CHM safety, only seven (13.7%) SRs reported adverse effects which were originated from CHM usage. Results from these seven SRs indicated that adverse events from CHM were mild, but a firm conclusion on the safety of CHM usage cannot be made as discovery of rare and longer term toxicities would require case-control and retrospective cohort designs. In the future, well reported observational studies and RCTs are needed to clarify the presence of short and long term toxicities of CHM.

Limitations on reporting were also noted among trials included in the SRs. Many trials were judged to have unclear risk of bias by the systematic reviewers, reflecting the lack of compliance to the CONSORT guideline for reporting. It is unfortunate that poor reporting practice does not improve despite the availability of Chinese CONSORT. This has limited us from excluding SRs that mainly report results from trials with high risk of bias, and the potential impact of this on the trustworthiness of the results should be highlighted. In addition, since the clinical evidence presented in all SRs were mainly obtained from trial reports published in mainland China, there was a potential risk of positive publication bias, although this phenomenon is not restricted to Chinese publications. To prevent publication bias, it is recommended that all clinical trials protocols on the topic should register with a recognized platform (e.g. the Chinese Clinical Trial Registry).

Although we did not set restriction on QoL measurement tool in our eligibility criteria, all included SRs reported such outcome using the KPS. KPS only measure general performance status, which might not be sufficient for assessing QoL of cancer patients comprehensively. Future trials are suggested to adopt more specific QoL measurement tool such as the Short Form 36 questionnaire, and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-core 30.

Major contributions of this overview are to comprehensively summarize; and to critically appraise all available evidence on CHM for cancer palliative care. Limitations on both reporting and methodological rigor of the existing SRs as well as primary studies were identified and suggestions were made on how these can be improved of future studies on this area. Clinical questions that are waiting for further researches were also identified through this study.

In conclusion, current clinical evidence indicated that CHM may be considered as a palliative care option for improving QoL among cancer patients. There are conflicting results on the effectiveness of CHM in prolonging survival and in reducing chemotherapy and/or radiotherapy related toxicities. Quality of evidence is moderate for these three outcomes. Also, future trials are suggested to investigate the effectiveness of CHM in managing common symptoms like pain, fatigue, anorexia, insomnia, limbs edema and constipation, in which conventional care options for these common cancer related symptoms were limited. Methodological quality of SRs in CHM for cancer palliative care is not satisfactory. To provide more rigorous evidence on the effectiveness of CHM, future SRs and trials must adhere to high methodological and reporting standards.

Methods

Criteria for considering meta-analyses for inclusion. This overview only included SR with meta-analysis that quantitatively summarized evidence on CHM for cancer palliative care. SR is defined as an “attempt to identify, appraise and synthesize all the empirical evidence that meets pre-specified eligibility criteria to answer a given research question”, in accordance to the Cochrane Handbook version 5.1.0. Any SRs that meet the following criteria were included in this overview: i) Cochrane SR or non-Cochrane SR focusing on cancer palliative care with meta-analysis conducted; ii) meta-analyses must pooled clinical trials that evaluate the effectiveness of at least one CHM indexed in the 2010 China Pharmacopeia Chinese herbal medicine index. The protocol of this overview has been registered in PROSPERO (http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID = CRD42015016171).

Participants. SR including clinical trials on patients diagnosed with any type of cancer and received at least one form of CHM for supportive or palliative care was considered eligible.

Interventions & control. CHM of any dosage form or route of administration was considered eligible in this overview. We included SRs that include studies providing any type of control treatment without CHM. These interventions include conventional treatment, placebo, chemotherapy, radiotherapy, or no treatment.
Outcomes of interest. With an aim to provide a comprehensive picture of available clinical evidence on CHM for cancer palliative care, we included all cancer or treatment related outcomes measured using validated approaches. Special attention was paid to those symptoms that are frequently experienced by cancer patients but limited treatment choices are available from conventional medicine. These outcomes include cancer related pain, fatigue, anorexia, insomnia, limbs edema and constipation.

Literature search. We conducted a comprehensive literature search in seven databases from their inception till July 2014. Both international databases (MEDLINE, EMBASE, Cochrane Database of Systematic Reviews (CDSR) and Database of Abstracts of Reviews of Effect (DARE)) and Chinese databases (Chinese Biomedical Databases (CBM), Wan Fang Digital Journals and Taiwan Periodical Literature Databases) were searched to identify potential SRs. Specialized search filter for reviews were used for MEDLINE and EMBASE. Detailed search strategies are reported in Appendix 1.

Literature selection, data extraction, methodological quality and quality of evidence assessment. All retrieved citations were screened and assessed for their eligibility according to the inclusion criteria. For duplicate publications, the most updated version was selected.

The following data were extracted from each included SR: i) basic characteristics of the SR, including search date, number of included studies, total number of patients and bibliographic information; ii) detailed information on study design and patient, intervention, control and outcomes; and iii) statistical results, including pooled effects of each comparison for each outcome.

Methodological quality of included SRs was assessed with the Methodological Quality of Systematic Reviews (AMSTAR) Instrument, which was shown to be a reliable and valid tool for assessing the methodological quality of SRs.

Eleven aspects were assessed by using AMSTAR, with each aspect being judged as yes, no, can’t answer or not applicable based on the information provided. Detailed operational guide for AMSTAR is provided in Appendix 2.

Quality of evidence for each outcome was assessed using the Chinese and Integrative Medicine Evidence Rating System (CHIMERAS). Quality of evidence was judged across five levels (very low, low, moderate, high and very high) by considering rigors of both qualitative (direction of effect) and quantitative (effect size) conclusions.

Literature selection, data extraction, methodological quality and quality of evidence assessment were conducted by two researchers independently, with any disagreement resolved by discussion and consensus. Unresolved discrepancy was managed by a third reviewer.

Data synthesis. The effectiveness of CHM treatments was assessed at review level. We did not re-analyze the data of the primary trials included in the SR. We extracted the pooled effect estimation from each meta-analysis. Pooled relative risk (RR) or odds ratio (OR) for dichotomous outcomes, and mean difference (MD) for continuous outcomes accompanied with respective 95% confidence interval (CI) were reported.

References
1. Sepulveda, C., Marlin, A., Yoshida, T. & Ulrich, A. Palliative care: The world health organization's global perspective. J Pain Symptom Manag 24, 91–96, doi: 10.1016/S0885-3924(02)00440-2 (2002).
2. Murray, S. A., Kendall, M., Boyd, K. & Sheikh, A. Illness trajectories and palliative care. BMJ 330, 1007–1011, doi: 10.1136/ bmj.330.7498.1007 (2005).
3. Temel, J. S. et al. Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer. N Engl J Med 363, 733–742, doi: 10.1056/NEJMoal000678 (2010).
4. Levy, M. et al. NCCN clinical practice guidelines in oncology: palliative care. J Natl Compr Canc Netw 7, 436 (2009).
5. Ferris, F. D. et al. Palliative cancer care a decade later: accomplishments, the need, next steps – from the American Society of Clinical Oncology. J Clin Oncol 27, 3052–3058, doi: 10.1200/jco.2008.20.1558 (2009).
6. Sepulveda, C., Marlin, A., Yoshida, T. & Ulrich, A. Palliative Care: The World Health Organization’s Global Perspective. J Pain Symptom Manage 24, 91–96, doi: http://dx.doi.org/10.1056/S0885-3924(02)00440-2 (2002).
7. Zimmermann, C., Riechelmann, R., Krzyzanowska, M., Rodin, G. & Tannock, I. Efficacy of specialized palliative care: A systematic review. JAMA 299, 1698–1709, doi: 10.1001/jama.299.14.1698 (2008).
8. Pachman, D. R., Barton, D. L., Swetz, K. M. & Loprinzi, C. L. Troublesome Symptoms in Cancer Survivors: Fatigue, Insomnia, Neuropathy, and Pain. J Clin Oncol 30, 3687–3696, doi: 10.1200/jco.2012.41.7238 (2012).
9. Qi, F. et al. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends 4, 297–307 (2010).
10. Gai, R. Y. et al. Dynamic of modernizing traditional Chinese medicine and the standards system for its development. Drug Discov Ther 2, 2–4 (2008).
11. Konkimalla, V. B. & Efferth, T. Evidence-based Chinese medicine for cancer therapy: J Ethnopharmacol 116, 207–210, doi: http://dx.doi.org/10.1016/j.jep.2007.12.009 (2008).
12. Molassiotis, A., Potratz, B. & Cheng, K. K. F. A systematic review of the effectiveness of Chinese herbal medication in symptom management and improvement of quality of life in adult cancer patients. Complement Ther Med 17, 92–120, doi: 10.1016/j. ctm.2008.11.002 (2009).
13. Li, S. G. et al. The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE [Electronic Resource] 8, e57604 (2013).
14. Reville, B., Axelrod, D. & Maury, R. Palliative Care for the Cancer Patient. Prim Care 36, 781–810, doi: http://dx.doi.org/10.1016/j. pop.2009.07.010 (2009).
15. Chung, V. C. et al. Are meta-analyses of Chinese herbal medicine trials trustworthy and clinically applicable? A cross-sectional study. J Ethnopharmacol 162, 47–54, doi: 10.1016/j.jep.2014.12.028 (2014).
16. Ho, R. et al. Methodological quality of meta-analyses on treatments for chronic obstructive pulmonary disease. NPJ Prim Care Respir Med 25, 14102, doi: 10.1038/npjpcrm.2014.102 (2014).
17. Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, doi: 10.1136/bmj.b2700 (2009).
18. Moher, D., Liberati, A., Tetzlaff, J., G. Altman, D. & Group, T. P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition). Journal of Chinese Integrative Medicine [Chinese] 7, 889–896 (2009).
Effectiveness of Chinese herbal medicine for cancer palliative care: overview of systematic reviews with meta-analyses.

How to cite this article: Chung, V. C. H. et al. Effectiveness of Chinese herbal medicine for cancer palliative care: overview of systematic reviews with meta-analyses. Sci. Rep. 5, 18111; doi: 10.1038/srep18111 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/